Cystic Fibrosis

Is No Way to Live

   
  • CF is a genetic disease: death from lung failure is late 20’s (average)
  • Quality of life is poor, treatment burden high. Lung transplants common
 

Solution:

Nanoparticle Gene Therapy

STEP 1

Working CF gene formulated with HK polymer to form a nanoparticle
STEP 2

Booster rocket
(PEG-ylation) added to nanoparticle fired (inhaled) at the lung
STEP 3

Booster rocket falls away and the HK polymer transfects the CF gene to the cell
STEP 4

Entire Rocket is <100nm to get through the 140nm pores in thick CF mucus

Delivery, Delivery & Delivery

Strong Transfection Data:

Flow Cytometry

 

GREEN FLUORESCENT PROTEIN ACTIVITY: 72 HOURS

 

Up to 48% of all cells transfected and 32 times better than control (DNA only).

Directors

Dr Noreen Henig

  • CMO at Breath Theraputics
  • Special Advisor, CMO and Chief Development officer at Pro QR
  • Senior Director of Global Respiratory at Gilead Sciences, Inc.
  • Many years of experience as a Director of Adult Cystic Fibrosis Care Centers

Daniel E. Levy, PHD

  • CEO of DEL BioPharma LLC
  • Director of Synthetic Chemistry at Intradigm - Corporation pursuing nanoparticle delivery vehicles for siRNA therapeutics.
  • Glycomed Inc., COR Therapeutics, Scios, Inc.

Mr John Bulicek

  • 25 years experience in investment banking in New York
  • Senior leadership positions within key Global Investment Banks including UBS, BNP Paribas, Commerzbank, and Canaccord Genuity
  • Owner corporate advisory firm Bulicek and Co

Mr Andrew Venables

  • 25+ years experience in law, finance and economics, including 10 years as a Partner of a leading corporate law firm. Listing CFO in oil and gas.
  • Experienced in financing gene therapy strategies for treating cystic fibrosis
  • CF Dad with extensive connections in the CF community
  •   avenables@loxegen.net

 

Scientific Advisory Board: Four World leading CF Professors from Canada, the USA and Israel.